Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Healthcare Biotechnology
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its... see more

Bullboard (TSX:MDP)

View:
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Comment by Napcooon May 21, 2024 11:11pm

RE:RE:This article favor Treo over busulfan

Published on May 26, 2022, announced NDA resubmission on July 25, 2022, FDA rejected on September x https://onlinelibrary.wiley.com/doi/10.1002/ajh.26620
90
Discussion
Comment by Napcooon May 21, 2024 10:47pm

RE:RE:RE:This article favor Treo over busulfan

On treosulfan, we are pleased to report that the data collection phase of medac's effort to respond to the FDA's information requests on treosulfan is now complete," Mr d'Entremont ...more  
131
Discussion
Comment by Napcooon May 21, 2024 10:40pm

RE:RE:This article favor Treo over busulfan

An NDA includes all animal and human data and analyses of the data, as well as information about how the drug behaves in the body and how it is manufactured. When an NDA comes in, the FDA has 60 days ...more  
110
Discussion
Comment by Napcooon May 21, 2024 10:26pm

RE:This article favor Treo over busulfan

The second published by nature favor Treo https://www.nature.com/articles/s41409-024-02269-4
85
Discussion
Post by Napcooon May 21, 2024 10:12pm

This article favor Treo over busulfan

https://www.nature.com/articles/s41409-023-02135-9
159
Discussion
Comment by Napcooon Mar 29, 2024 9:00pm

RE:Trend Continues

He is just trying to earn a living, there isn't any truth out of him
84
Discussion
Post by TheMediaon Mar 29, 2024 3:34pm

Trend Continues

March26th Equity Guru/Chris Parry writes up the company. Another company suckered out of their money by this scam out-fit. Stocks do nothing but lose money for anyone following this useless out-fit.
175
Discussion
Comment by Napcooon Mar 28, 2024 6:50pm

RE:RE:Ixinity replacement therapy

Gene therapy needs time to verify the long term results, giving replacement therapy such as ixinity a break https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b
78
Discussion
Comment by Napcooon Mar 28, 2024 6:40pm

RE:RE:Ixinity replacement therapy

FDA-approved gene therapies In November 2022, the Food and Drug Administration approved Hemgenix, CSL Behring's hemophilia B gene therapy. Researchers at Children’s Hospital of Philadelphia are ...more  
79
Discussion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities